{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "COMP", "name": "Compass, Inc.", "url": "https://orbyd.app/dossiers/COMP/", "json_url": "https://orbyd.app/dossiers/COMP.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": "LOW", "archetype": { "code": "a4", "n": 4 }, "current_thesis": "Now stretched into a binary ~2026-07-29 Q2 print ($4.0–4.2B guide) with an open NY AG antitrust probe.", "invalidation_trigger": "A weekly close below $11 loses the luxury-demand breakout above the June AG-dip shelf and reopens the ~$9.78 June low; a formal NY AG divestiture/CID demand or a Q2 revenue miss versus the $4.0–4.2B guide is the secondary break.", "catalyst_date": "2026-08-11", "outcome": "PLAYED_OUT", "outcome_date": "2026-08-05", "invalidation_fired": false, "themes": [ "housing-homebuilders-proptech", "semi-foundry-equipment", "cyclical-industrials" ], "tags": [], "sources": [], "notes": [ "Headline YoY growth is inflated by the 2026-01-09 Anywhere close — judge organic momentum on pro-forma figures (Brokerage GTV +15.9% pro forma vs +98.2% reported in Q2).", "NY AG antitrust inquiry opened 2026-06-03 remains open with no timetable and no publicly disclosed CID as of 2026-08-07.", "Analyst targets bracket spot widely: Goldman $12 Neutral to Oppenheimer $18 Outperform, per actions dated 2026-08-05/2026-08-06.", "CEO-affiliated trusts sell under a Rule 10b5-1 plan adopted 2026-03-03; recurring Form 4 sales are pre-scheduled and not discretionary decisions.", "Company stated intent to redeem the $500M 9.75% notes when first callable in Q2 2027 — the interest-expense step-down is a 2027 event, not a 2026 one.", "Revenue is volume-driven: existing-home-sales transaction counts and the mortgage path matter more than home-price levels." ], "body_markdown": "## Current Thesis\nThe binary that defined the last note resolved on 2026-08-04, and it resolved well. Q2 revenue of $4.306B beat the $4.081B consensus and cleared the top of the company's own $4.0–4.2B guide; adjusted EBITDA of $363M printed above the guided $310–350M range; GAAP net income was $92M. The Year-1 Anywhere net cost-synergy target of $300M was actioned five months ahead of plan and raised to $330M, with the 2026 realized goal lifted from $200M to $220M against an unchanged three-year $500M target. Q3 guidance of $3.85–4.05B revenue and $275–305M adjusted EBITDA was set above the $3.745B street revenue number. Price has not followed the fundamentals: the 2026-08-07 close of $12.58 sits 7.4% below the $13.58 52-week high, with RSI(14) at 59.9 after a 44.3% three-month advance. The narrative leg on offer is the remaining $170M of the three-year synergy plan converting to EBITDA while pro-forma transaction growth stays positive. The overhang is unchanged: the New York Attorney General's antitrust inquiry opened 2026-06-03 is still open and carries no calendar.\n\n**Life-cycle: MATURING.** Dating it: six sell-side actions landed in seven sessions — UBS Buy $17 (2026-07-31), then post-print Oppenheimer Outperform $18, Barclays Overweight $16, Wells Fargo Equal-Weight $13 and Goldman Neutral $12 (all 2026-08-05), followed by Zelman's downgrade to Neutral with a $13.50 target on 2026-08-06. A beat-and-raise that generates target increases across the board *and* a valuation downgrade inside 48 hours, while the tape closes below its post-print high, is a story that is understood and still working rather than one pulling in a new bid.\n\n## Bull Case\n- Q2 2026 (2026-08-04): revenue $4.306B vs $4.081B consensus, adjusted EBITDA $363M vs a $310–350M guide — both above the high end the company set on 2026-05-05.\n- Synergy capture is running ahead of schedule: full Year-1 $300M actioned five months early, target raised to $330M; 2026 realized raised to $220M ($150M through the P&L, $70M capex). The three-year $500M target is reaffirmed, so roughly $170M of the plan is still unbanked.\n- Organic momentum, on the pro-forma basis that strips the 2026-01-09 merger: Brokerage GTV $155.2B, +15.9% pro forma YoY on 153,009 transactions (+7.4% pro forma). Management put market outperformance at 1,000bps in Q2 versus 580bps in Q1.\n- Balance sheet improved without an equity raise: operating cash flow $191M, free cash flow $180M, cash $694M (+$210M QoQ). The company stated it intends to redeem the $500M 9.75% notes when first callable in Q2 2027 — an interest-expense step-down already flagged.\n- Agent economics stabilised: retention 95.5% in Q2 versus 94.1% in Q1, with 2,816 gross additions.\n- Q3 guide is above the street on both lines ($3.85–4.05B revenue vs $3.745B estimate; $275–305M adjusted EBITDA), which removes the \"guided into a beat, then reset\" pattern that usually follows a synergy raise.\n\n## Bear Case\n- The print was not clean on the bottom line: Q2 EPS of $0.11 missed the $0.12 estimate despite the revenue beat, and FY2026 non-GAAP opex guidance was raised to $2.75–2.80B from $2.70–2.75B, including $35M from a July M&A closure.\n- Headcount went the wrong way sequentially: 83,184 agents versus 84,187 in Q1, attributed to separating low-productivity agents. The improvement in retention and the decline in the roster are the same event described twice.\n- Franchise mix is diluting the royalty stream: net royalty per side of $505 was down 14.6% YoY on lower average sales prices from newly acquired brands, even as Franchise GTV grew 11.7% pro forma.\n- The NY AG inquiry (opened 2026-06-03) has produced no public resolution, no CID disclosure and no timetable. Reporting at the time described the antitrust division contacting rival New York brokerage leaders; the combined entity is the largest US residential firm at 340,000+ agents and franchisees. That is a live, unscheduled headline risk that gapped the stock in early June.\n- Volume, not price, is the revenue driver, and the volume series is soft: NAR's June existing-home sales report showed a 2.4% decrease.\n- Valuation is now a stated sell-side objection: Zelman & Associates cut to Neutral on 2026-08-06 with a $13.50 target — above spot, but the first downgrade of the leg.\n\n## Setup & Price Structure\n- Measured: close $12.58 on 2026-08-07; 52-week high $13.58; distance from high -7.4%; three-month return +44.3%; RSI(14) 59.9.\n- The pre-print July range is observable from third-party records: Form 4 executions on 2026-07-01 ran $12.22–$12.68, and the stock was quoted around $12.70 on 2026-07-15. The 08-07 close at $12.58 sits back inside that band.\n- Inferred, not measured: the $13.58 52-week high was most plausibly printed on the earnings reaction (transcript coverage on 2026-08-04 described shares up ~11% after hours). If so, the beat-and-raise gap has been substantially retraced within the same week — no intraday tape is cited here to confirm the sequence.\n- Crowding/positioning observables, stated without a verdict: five price-target increases and one downgrade between 2026-07-31 and 2026-08-06; a target bracket spanning Goldman $12 to Oppenheimer $18 around a $12.58 spot; Pre-scheduled plan sales are mechanical; the relevant point is that supply prints in this price zone.\n- RSI at 59.9 after a 44% quarter says momentum has cooled off the high rather than broken; there is no evidence yet of a completed base above the July range.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-11, 10:00 ET** — NAR existing-home sales, July. The volume series that Brokerage GTV tracks; June printed -2.4%.\n- **~2026-08-27 (est.)** — NAR pending home sales, July. Forward-looking read on Q3 transaction sides.\n- **~2026-11-03 (est.), beyond the 30-day window** — Q3 2026 print, the first test of the $3.85–4.05B / $275–305M guide and of whether the $330M actioned synergy figure converts.\n\n## Elapsed catalysts\n\n- **Unscheduled, ongoing** — NY AG antitrust inquiry (opened 2026-06-03). Any CID, subpoena or divestiture demand would arrive without a calendar date; equally, weeks passing with no filing is itself information. *(passed 67d ago)*\n\n## What Would Change Our Mind\nThe structure that matters is the July shelf around $12.20–$12.70 that the stock has fallen back into. Losing it would mean the beat-and-raise bought no durable ground, and would put the 2026-06-22 AG-dip low near $9.78 back in play. Gradeable version: a weekly close below $11.50. Secondary conditions, either of which breaks the fundamental leg independently of price: a New York AG civil investigative demand, subpoena or divestiture request becoming public; or a Q3 revenue print below the $3.85B guidance floor, which would mean the pro-forma transaction growth (+7.4% in Q2) reversed within one quarter. A third, slower break would be the FY2026 non-GAAP opex guide being raised again — it already went to $2.75–2.80B on 2026-08-04 — while realized synergies stay at $220M, since the re-rate rests on cost capture outrunning integration spend.\n\n## Correlation Notes\n- Revenue is levered to transaction sides and GTV, so the name trades with the existing-home-sales volume series and the 30-year mortgage path rather than with home prices; the 2026-08-11 NAR release is the cleanest scheduled read on that factor.\n- Peer complex for beta purposes: listed brokerage and residential-transaction platforms (EXPI, RMAX, ZG, OPEN) plus rate-sensitive housing baskets. Anywhere is no longer an independent comparable following the 2026-01-09 close.\n- The Franchise segment adds a royalty-stream correlation with brand mix and average sales price — net royalty per side fell 14.6% YoY in Q2 while segment GTV rose, so the two lines can diverge.\n- Idiosyncratic decoupling risk: the 2026-06-03 NY AG headline moved COMP independently of the housing complex. Regulatory news flow is the one factor that breaks the peer correlation on any given day.", "first_seen": "2026-06-28", "last_analyzed": "2026-08-09T19:46:01+00:00", "last_synthesized": "2026-08-09", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }